News FDA approves Incyte's Pemazyre for rare bile duct cancer The FDA has approved Incyte's Pemazyre (pemigatinib), the first targeted treatment for a rare cancer of the bile duct.
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
